GlaxoSmithKline Pharmaceuticals received a GST demand order of Rs. 52.53 lakh from Bihar authorities for FY 2021-22 due to a GST credit mismatch. The company says there is no financial impact, and it is evaluating the order for appropriate action.
GlaxoSmithKline Pharmaceuticals Limited has received a GST demand order from the Bihar Central GST authorities for the fiscal year 2021-22. The order, dated 11th November 2025, was received by the company on 12th December 2025. The total demand raised is Rs. 52,52,988, comprising tax of Rs. 47,75,444 and a penalty of Rs. 4,77,544, with interest not quantified.
Notable Updates:
-
The demand relates to a GST credit issue, specifically a mismatch between the company’s GST returns and details reported by suppliers.
-
The authority involved is the Assistant Commissioner, CGST & CX, Patna Central Division, Patna.
-
The company has clarified that there is no material impact on its financial operations at this stage.
-
GlaxoSmithKline is currently evaluating the order and will take appropriate actions in due course.
Major Takeaways:
-
The demand order is for FY 2021-22 and highlights a GST credit discrepancy.
-
The company is assessing the implications and next steps, but financial operations remain unaffected for now.
-
This is part of ongoing regulatory scrutiny faced by several pharmaceutical companies in recent months.
Important Points:
-
The total demand is Rs. 52,52,988, with Rs. 47,75,444 as tax and Rs. 4,77,544 as penalty.
-
No quantified interest has been specified in the order.
-
The issue stems from a mismatch in GST returns and supplier-reported details.
-
The company’s response will be guided by further internal evaluation.
Source: NSE Corporate Announcement, Investywise, BSE Announcement